Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 17, 2008, Pages 6302-6307

  Kravchenko, J E ^a,b   Ilyinskaya, G V ^a,b,c   Komarov, P G ^d,f   Agapova, L S ^a,c   Kochetkov, D V ^a,b   Strom, E ^d,f   Frolova, E I ^e   Kovriga, I ^e   Gudkov, A V ^a,g   Feinstein, E ^d   Chumakov, P M ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^c Cancer Research Center   (Russian Federation)

^d Quark Biotech Inc   (United States)

^e SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^f CLEVELAND BIOLABS INC   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cancer therapy; p73 family; Tumor suppressors

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53; PROTEIN P73; RETRA; 2 (4,5 DIHYDRO 1,3 THIAZOL 2 YLTHIO) 1 (3,4 DIHYDROXYPHENYL)ETHANONE; 2-(4,5-DIHYDRO-1,3-THIAZOL-2-YLTHIO)-1-(3,4-DIHYDROXYPHENYL)ETHANONE; CATECHOL DERIVATIVE; DNA BINDING PROTEIN; MESSENGER RNA; MUTANT PROTEIN; NUCLEAR PROTEIN; THIAZOLE DERIVATIVE; TP73 PROTEIN, HUMAN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RNA INTERFERENCE; ANIMAL; CHEMISTRY; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOLECULAR LIBRARY; NEOPLASM; PATHOLOGY; REPORTER GENE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CATECHOLS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; MICE; MUTANT PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; RNA, MESSENGER; SMALL MOLECULE LIBRARIES; THIAZOLES; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 44049091429     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0802091105     Document Type: Article

References (21)

1. Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC (2004) Tp53 Mutation Spectra and Load: A Tool for Generating Hypotheses on the Etiology of Cancer. [International Agency for Research on Cancer (IARC), Lyon, France], pp 247-270.
2. Levrero M, et al. (2000) The p53/p63/p73 family of transcription factors: Overlapping and distinct functions. J Cell Sci 113:1661-1670.
3. Flores ER, et al. (2005) Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7:363-373.
4. Irwin MS, et al. (2003) Chemosensitivity linked to p73 function. Cancer Cell 3:403-410.
5. Marabese M, Vikhanskaya F, Broggini M (2007) p73: A chiaroscuro gene in cancer. Eur J Cancer 43:1361-1372.
6. Coates PJ (2006) Regulating p73 isoforms in human tumours. J Pathol 210:385-389.
7. Muller M, et al. (2006) One, two, three - p53, p63, p73 and chemosensitivity. Drug Resist Update 9:288-306.
8. Davison TS, et al. (1999) p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J Biol Chem 274:18709-18714.
9. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21:1874-1887.
10. Li Y, Prives C (2007) Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26:2220-2225.
11. Strano S, et al. (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277:18817-18826.
12. Bell HS, et al. (2007) A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest 117:1008-1018.
13. Wang W, Kim SH, El-Deiry WS (2006) Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci USA 103:11003-11008.
14. Vayssade M, et al. (2005) P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells. Int J Cancer 116:860-869.
15. Amin AR, Paul RK, Thakur VS, Agarwal ML (2007) A novel role for p73 in the regulation of Akt-Foxo1a-Bim signaling and apoptosis induced by the plant lectin, Concanavalin A. Cancer Res 67:5617-5621.
16. Amin AR, et al. (2007) SHP-2 tyrosine phosphatase inhibits p73-dependent apoptosis and expression of a subset of p53 target genes induced by EGCG. Proc Natl Acad Sci USA 104:5419-5424.
17. Razorenova OV, Ivanov AV, Budanov AV, Chumakov PM (2005) Virus-based reporter systems for monitoring transcriptional activity of hypoxia-inducible factor 1. Gene 350:89-98.
18. Bykov VJ, et al. (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8:282-288.
19. Sullivan A, Lu X (2007) ASPP: A new family of oncogenes and tumour suppressor genes. Br J Cancer 96:196-200.
20. Sablina AA, et al. (2005) The antioxidant function of the p53 tumor suppressor. Nat Med 11:1306-1313.
21. Strom E, et al. (2006) Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2:474-479.